These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 28405764)

  • 21. The effects of ARID1A mutations on colorectal cancer and associations with PD-L1 expression by stromal cells.
    Kamori T; Oki E; Shimada Y; Hu Q; Hisamatsu Y; Ando K; Shimokawa M; Wakai T; Oda Y; Mori M
    Cancer Rep (Hoboken); 2022 Jan; 5(1):e1420. PubMed ID: 34042312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.
    Marisa L; Svrcek M; Collura A; Becht E; Cervera P; Wanherdrick K; Buhard O; Goloudina A; Jonchère V; Selves J; Milano G; Guenot D; Cohen R; Colas C; Laurent-Puig P; Olschwang S; Lefèvre JH; Parc Y; Boige V; Lepage C; André T; Fléjou JF; Dérangère V; Ghiringhelli F; de Reynies A; Duval A
    J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MSI status is associated with distinct clinicopathological features in BRAF mutation colorectal cancer: A systematic review and meta-analysis.
    Wu M; Kim YS; Ryu HS; Choi SC; Kim KY; Park WC; Kim MS; Myung JY; Choi HS; Kim EJ; Lee MY
    Pathol Res Pract; 2020 Jan; 216(1):152791. PubMed ID: 31866097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer.
    Seppälä TT; Böhm JP; Friman M; Lahtinen L; Väyrynen VM; Liipo TK; Ristimäki AP; Kairaluoma MV; Kellokumpu IH; Kuopio TH; Mecklin JP
    Br J Cancer; 2015 Jun; 112(12):1966-75. PubMed ID: 25973534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High endothelial venules are associated with microsatellite instability, hereditary background and immune evasion in colorectal cancer.
    Pfuderer PL; Ballhausen A; Seidler F; Stark HJ; Grabe N; Frayling IM; Ager A; von Knebel Doeberitz M; Kloor M; Ahadova A
    Br J Cancer; 2019 Aug; 121(5):395-404. PubMed ID: 31358939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.
    Sudoyo AW; Kurniawan AN; Kusumo GD; Putra TP; Rexana FA; Yunus M; Budiyati AD; Kurniawan D; Utama A; Utomo AR
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3421-3427. PubMed ID: 31759368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas.
    Inaguma S; Lasota J; Wang Z; Felisiak-Golabek A; Ikeda H; Miettinen M
    Mod Pathol; 2017 Feb; 30(2):278-285. PubMed ID: 27813511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subtyping of microsatellite instability-high colorectal cancer.
    Hu W; Yang Y; Qi L; Chen J; Ge W; Zheng S
    Cell Commun Signal; 2019 Jul; 17(1):79. PubMed ID: 31331345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic role of tumour-infiltrating lymphocytes and macrophages in relation to MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients.
    Aasebø K; Bruun J; Bergsland CH; Nunes L; Eide GE; Pfeiffer P; Dahl O; Glimelius B; Lothe RA; Sorbye H
    Br J Cancer; 2022 Jan; 126(1):48-56. PubMed ID: 34671130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase ε (POLE).
    Forgó E; Gomez AJ; Steiner D; Zehnder J; Longacre TA
    Histopathology; 2020 Feb; 76(3):366-374. PubMed ID: 31479159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome.
    Toon CW; Walsh MD; Chou A; Capper D; Clarkson A; Sioson L; Clarke S; Mead S; Walters RJ; Clendenning M; Rosty C; Young JP; Win AK; Hopper JL; Crook A; von Deimling A; Jenkins MA; Buchanan DD; Gill AJ
    Am J Surg Pathol; 2013 Oct; 37(10):1592-602. PubMed ID: 23797718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Predictive Value of CD3+/CD8+ Lymphocyte Infiltration and PD-L1 Expression in Colorectal Cancer.
    Liu J; Li J; Luo F; Wu S; Li B; Liu K
    Curr Oncol; 2023 Oct; 30(11):9647-9659. PubMed ID: 37999119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular profile and copy number analysis of sporadic colorectal cancer in Taiwan.
    Lin CH; Lin JK; Chang SC; Chang YH; Chang HM; Liu JH; Li LH; Chen YT; Tsai SF; Chen WS
    J Biomed Sci; 2011 Jun; 18(1):36. PubMed ID: 21645411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.
    Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Takahashi A; Kakuta M; Nishimura Y; Yamaguchi K
    J Surg Oncol; 2014 Dec; 110(8):982-8. PubMed ID: 25154726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers.
    Schwitalle Y; Kloor M; Eiermann S; Linnebacher M; Kienle P; Knaebel HP; Tariverdian M; Benner A; von Knebel Doeberitz M
    Gastroenterology; 2008 Apr; 134(4):988-97. PubMed ID: 18395080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
    Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
    Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
    El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
    J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer.
    Horimoto Y; Thinzar Hlaing M; Saeki H; Kitano S; Nakai K; Sasaki R; Kurisaki-Arakawa A; Arakawa A; Otsuji N; Matsuoka S; Tokuda E; Arai M; Saito M
    Cancer Sci; 2020 Jul; 111(7):2647-2654. PubMed ID: 32449246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status.
    Michael-Robinson JM; Biemer-Hüttmann A; Purdie DM; Walsh MD; Simms LA; Biden KG; Young JP; Leggett BA; Jass JR; Radford-Smith GL
    Gut; 2001 Mar; 48(3):360-6. PubMed ID: 11171826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.